No News?? For emphasis-- * "More than 15 abstracts were presented on SEPR's DCL, Xopenex, norastemizole, and formoterol at this past weekend's American Academy of Allergy, Asthma, and
Immunology meeting. The majority of the data focused on DCL, Sepracor and
partner Schering-Plough's second-generation Claritin. We believe the data
indicates that DCL is a safe, well-tolerated, and potent H1 receptor
antagonist. Partner Schering-Plough has filed an NDA for DCL, and we
anticipate approval in late 2000. Head-to-head chamber study data appear to
indicate that SEPR's norastemizole has a superior onset of action (OA) compared
to Schering's currently marketed Claritin. More specifically, norastemizole
has 20-minute OA compared to Claritin's 140 minutes. Xopenex Grand Symposia and
additional clinical data could be incrementally positive to marketing efforts
for the prdouct."
Ed, at least 5 or more of these abstracts were presented and commented upon by posters more technically proficient than myself, in the YC. Their conclusions were generally positive, but no block buster results. May be "they" were expecting a positive surprise.
Considering this conference concluded 3/6 the stock reaction has been poor. It seems we simultaneously had the full amount of the recent funding option converted in the last few days as well. |
